iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference Catherine Pickering, CEO of iOnctura, will discuss the company's innovative cancer therapies at the upcoming J.P. Morgan Healthcare Conference in January.

iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference #United_States #cancer_therapy #San_Francisco #iOnctura #roginolisib

iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial iOnctura announces the initiation of its Phase I/II trial evaluating roginolisib for myelofibrosis patients not responding to JAK inhibitors.

iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial #Switzerland #Geneva #Myelofibrosis #roginolisib #ASH2025

iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options iOnctura's expansion of roginolisib trials to the US aims to revolutionize cancer treatment strategies for hard-to-treat cancers.

iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options #United_States #Cambridge #oncology #iOnctura #roginolisib

iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations iOnctura announces the appointment of Steven Sciuto as CFO and Michelle Tsai as COO, enhancing leadership to boost oncology portfolio success.

iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations #oncology #Netherlands #Amsterdam #iOnctura #roginolisib

iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib iOnctura has initiated a Phase I/II study targeting advanced non-small cell lung cancer, exploring the effectiveness of roginolisib combined with dostarlimab and chemotherapy.

iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib #Netherlands #Amsterdam #Lung_Cancer #iOnctura #roginolisib

iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment iOnctura has initiated a Phase II study for roginolisib, aimed at treating metastatic uveal melanoma, garnering orphan drug designation in Europe.

iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment #None #Amsterdam #iOnctura #roginolisib #uveal_melanoma

iOnctura achieves new clinical milestones in uveal melanoma therapy - PharmaTimes Successful phase 1 study highlights potential of roginolisib

#iOnctura #uvealmelanoma #uvealmelanomapatients #uvealmelanomatherapy #phase1study #roginolisib #phase1#DIONE01study #clinicalactivity #longtermsafety #ESMO #EuropeanSocietyforMedicalOncology #ImmunoOncology #allostericbindingmechanism #phase2study #OCULE01study
pharmatimes.com/news/ionctur...

iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment iOnctura has announced promising clinical results for roginolisib, a new treatment for uveal melanoma, showing improved survival rates.

iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment #Netherlands #Amsterdam #iOnctura #roginolisib #uveal_melanoma